Business
UCB announces new clinical data from its generalized myasthenia gravis (gMG) portfolio at the 2026 American Academy of Neurology (AAN) meeting
UCB, a global biopharmaceutical company, today announced data from two clinical studies assessing ZLP-AI in adult patients who are anti-AChR antibody positivegMG as well as in healthy volunteers. The studies evaluated the effectiveness of a ZLP- AI as a potential new alternative administration option, and the bioequivalence of ZLP-AI relative to ZLP-PFS. ZLP-AI is an investigational administration option for the treatment of gMG in adult patients who are anti-AChR antibody positive and the prese
About this update from United Community Banks, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"UCB will present additional studies and data analyses highlighting UCB's ongoing commitment to improving outcomes for people living with gMG","length":144,"tagName":"p"}]},{"val":[{"type":"text","content":"Two studies assessed the bioequivalence and effectiveness of zilucoplan auto-injector (ZLP-AI) administration compared with pre-filled syringe (ZLP-PFS)1","length":153,"tagName":"p"}]},{"val":[{"type":"text","content":"UCB is presenting 21 abstracts in total from its innovative neurology portfolio including 14 epilepsy abstracts and six myasthenia gravis (MG) abstracts at AAN 2026","length":169,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":466,"olType":false},{"type":"text","content":"ATLANTA, April 13, 2026 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced data from two clinical studies assessing ZLP-AI in adult patients who are anti-AChR antibody positivegMG as well as in healthy volunteers. The studies evaluated the effectiveness of a ZLP- AI as a potential new alternative administration option, and the bioequivalence of ZLP-AI relative to ZLP-PFS. ZLP-AI is an investigational administration option for the treatment of gMG in adult patients who are anti-AChR antibody positive and the presentation is currently not approved in the U.S.","length":595,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/UCB, Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/UCB, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":95,"url":"https://media.zenfs.com/en/prnewswire.com/b8934a241b3f4be76014bb4ac3438a0c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/HjbSkPCfjBQlXsmp4Za4Jg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE2Nw--/https://media.zenfs.com/en/prnewswire.com/b8934a241b3f4be76014bb4ac3438a0c","width":400,"height":95}},"href":"https://mma.prnewswire.com/media/677397/With_Tag_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"DV0013 was a Phase 3b open-label, multicenter study in adult patients with gMG self-administering zilucoplan via auto-injector once daily.1 DV0012 was a Phase 1, open-label, single-center, two-period crossover study in healthy adult volunteers to establish bioequivalence of zilucoplan delivered via an auto-injector pen compared with a pre-filled s...